Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (73 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Sep 2022 – 20 Aug 2026, limited by HDFC Nifty100 Quality 30 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC Nifty100 Quality 30 ETF | Nifty 100 |
|---|---|---|
| 23 Sep 2022 | ₹100.00 | ₹100.00 |
| 20 Jan 2023 | ₹99.64 | ₹102.55 |
| 19 May 2023 | ₹105.35 | ₹101.93 |
| 15 Sep 2023 | ₹118.31 | ₹113.49 |
| 12 Jan 2024 | ₹132.07 | ₹125.06 |
| 10 May 2024 | ₹136.36 | ₹129.30 |
| 06 Sep 2024 | ₹160.18 | ₹146.34 |
| 02 Jan 2025 | ₹149.76 | ₹141.26 |
| 01 May 2025 | ₹142.74 | ₹140.21 |
| 28 Aug 2025 | ₹149.04 | ₹141.54 |
| 25 Dec 2025 | ₹157.38 | ₹150.55 |
| 23 Apr 2026 | ₹149.96 | ₹141.63 |
| 20 Aug 2026 | ₹154.32 | ₹143.31 |
| Metric | HDFC NAV ₹59.49 Very High risk ★★☆☆☆ | Category median Other ETFs · 73 funds |
|---|---|---|
| +2.40% | +4.04% | |
| +11.17% | +10.87% | |
| — | +9.30% | |
| — | +11.96% | |
| +11.74% | +11.34% | |
| +8.42% | — | |
| +13.16% | +14.16% | |
| — | +14.63% | |
| — | +13.16% | |
| Risk | ||
| 12.54% | 14.74% | |
| 0.37 | 0.30 | |
| 0.52 | 0.42 | |
| -21.05% | -21.01% | |
| Nifty 100 | — | |
| +1.36% | +0.59% | |
| 0.97 | 1.00 | |
| 99.9% | 100.9% | |
| 92.1% | 97.8% | |
| 0.30% | 0.29% | |
| ₹20.91Cr | ₹143.12Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Arun Agarwal | — | |
| 23 Sep 2022 | — | |
| 30 | — | |
| 47.1% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.